Anebulo Pharmaceuticals, Inc.ANEBNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 75% recommend buying.

Consensus Rating

Buy

4 analysts·Low coverage

75%

Rating Distribution

Strong Buy

00%

Buy

375%

Hold

125%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 500% higher.

Bear Case

$6.00

+500%

Consensus

$6.00

+500%

Bull Case

$6.00

+500%

Price Range4 analysts

Low

Consensus

High

$6.00

Current Target

Current Price

$1.00

Upside to Target

$5.00

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.48(1 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+62.26%

EPS—

FY2028

Rev+188.40%

EPS—

FY2029

Rev—

EPS—

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+11.7%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Sep 18, 2023H.C. Wainwright

Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says

Target:$6.00

+83.5%from $3.27

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance